Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients.

The RaDaR tumor-informed assay was used to measure ctDNA over time in 276 prospectively collected samples from people with high-risk melanoma.

ESMO OpenPubMed 39549683DOI 10.1016/j.esmoop.2024.103978